431
Views
9
CrossRef citations to date
0
Altmetric
Original Article

Desmopressin in vitro effects on platelet function, monitored with Multiplate, ROTEM and Sonoclot

, , &
Pages 282-290 | Received 01 Aug 2015, Accepted 29 Jan 2016, Published online: 29 Feb 2016

References

  • Cash JD, Gader AM, da Costa J. Proceedings: the release of plasminogen activator and factor VIII to lysine vasopressin, arginine vasopressin, I-desamino-8-d-arginine vasopressin, angiotensin and oxytocin in man. Br J Haematol 1974;27:363–4.
  • Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975;30:81–93.
  • Franchini M. The use of desmopressin as a hemostatic agent: a concise review. Am. J. Hematol. Jof Hematology 2007;82:731–5.
  • Fuse I, Higuchi W, Mito M, Aizawa Y. DDAVP normalized the bleeding time in patients with congenital platelet TxA2 receptor abnormality. Transfusion 2003;43:563–7.
  • Lee HK, Kim YJ, Jeong JU, Park JS, Chi HS, Kim SB. Desmopressin improves platelet dysfunction measured by in vitro closure time in uremic patients. Nephron Clin Pract 2010;114:248–52.
  • Svensson PJ, Bergqvist PB, Juul KV, Berntorp E. Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding. Blood Rev 2014;28:95–102.
  • Reiter RA, Mayr F, Blazicek H, Galehr E, Jilma-Stohlawetz P, Domanovits H, Jilma B. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood 2003;102:4594–9.
  • Lethagen S, Nilsson IM. DDAVP-induced enhancement of platelet retention: its dependence on platelet-von Willebrand factor and the platelet receptor GP IIb/IIIa. Eur J Haematol 1992;49:7–13.
  • Rao AK, Ghosh S, Sun L, Yang X, Disa J, Pickens P, Polansky M. Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects. A double-blind placebo-controlled trial. Thromb Haemost 1995;74:1071–8.
  • Colucci G, Stutz M, Rochat S, Conte T, Pavicic M, Reusser M, Giabbani E, Huynh A, Thürlemann C, Keller P, Alberio L. The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects. Blood 2014;123:1905–16.
  • Mongan PD, Hosking MP. The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification. Anesthesiology 1992;77:38–46.
  • Schött U, Sollén C, Axelsson K, Rugarn P, Allvin I. Desmopressin acetate does not reduce blood loss during total hip replacement in patients receiving dextran. Acta Anaesthesiol Scand 1995;39:592–8.
  • Siller-Matula JM, Gouya G, Wolzt M, Jilma B. Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers. Thromb Haemost 2009;102:397–403.
  • Schött U, Johansson PI. Editorial. Bringing flow into haemostasis diagnostics. BJA 2013;111:864–7.
  • Horstman LL, Valle-Riestra BJ, Jy W, Wang F, Mao W, Ahn YS. Desmopressin (DDAVP) acts on platelets to generate platelet microparticles and enhanced procoagulant activity. Thromb Res 1995;79:163–74.
  • Calmer S, Ferkau A, Larmann J, Johanning K, Czaja E, Hagl C, Echtermeyer F, Goudeva L, Heuft HG, Theilmeier G. Desmopressin (DDAVP) improves recruitment of activated platelets to collagen but simultaneously increases platelet endothelial interactions in vitro. Platelets 2014;25:8–15.
  • Wun T, Paglieroni TG, Lachant NA. Desmopressin stimulates the expression of P-selectin on human platelets in vitro. J Lab Clin Med 1995;126:401–9.
  • Yang X, Disa J, Rao AK. Effect of 1-desamino-8-d-arginine vasopressin (DDAVP) on human platelets. Thromb Res 1990;59:809–18.
  • Gordz S, Mrowietz C, Pindur G, Park JW, Jung F. Effect of desmopressin (DDAVP) on platelet membrane glycoprotein expression in patients with von Willebrand's disease. Clin Hemorheol Microcirc 2005;32:83–7.
  • Tóth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96:781–8.
  • Balduini CL, Noris P, Belletti S, Spedini P, Gamba G. In vitro and in vivo effects of desmopressin on platelet function. Haematologica 1999;84:891–6.
  • Lethagen S, Olofsson L, Frick K, Berntorp E, Björkman S. Effect kinetics of desmopressin-induced platelet retention in healthy volunteers treated with aspirin or placebo. Haemophilia 2000;6:15–20.
  • Swieringa F, Lancé MD, Fuchs B, Feijge MAH, Solecka BA, Verheijen LPJ, Hughes KR, van Oerle R, Deckmyn H, Kannicht C, Heemskerk JWM, van der Meijden PEJ. Desmopressin treatment improves platelet function under flow in patients with postoperative bleeding. J Thromb Haemost 2015;13:1503–13.
  • Trummer A, Haarmeijer B, Werwitzke S, Wermes C, Ganser A, Budde U, Tiede A. Increased amounts of von Willebrand factor are bound to microparticles after infusion of desmopressin. Haemophilia 2013;19:236–41.
  • Weber CF, Dietrich W, Spannagl M, Hofstetter C, Jambor C. A point-of-care assessment of the effects of desmopressin on impaired platelet function using multiple electrode whole-blood aggregometry in patients after cardiac surgery. Anesth Analg 2010;110:702–7.
  • Wun T, Paglieroni T, Lachant NA. Physiologic concentrations of arginine vasopressin activate human platelets in vitro. Br J Haematol 1996;92:968–72.
  • Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006;4:312–19.
  • Tuman KJ, Spiess BD, McCarthy RJ, Ivankovich AD. Comparison of viscoelastic measures of coagulation after cardiopulmonary bypass. Anesth Analg 1989;69:69–75.
  • Johnston LR, Larsen PD, La Flamme AC, Harding SA. Methodological considerations for the assessment of ADP induced platelet aggregation using the Multiplate® analyser. Platelets 2013;24:303–7.
  • Ho CH, Chan IH. The influence of time of storage, temperature of storage, platelet number in platelet-rich plasma, packed cell, mean platelet volume, hemoglobin concentration, age, and sex on platelet aggregation test. Ann Hematol 1995;71:129–33.
  • Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009;157:148.e1–5.
  • Hellstern P, Stürzebecher U, Wuchold B, Haubelt H, Seyfert UT, Bauer M, Vogt A, Stürzebecher J. Preservation of in vitro function of platelets stored in the presence of a synthetic dual inhibitor of factor Xa and thrombin. J Thromb Haemost 2007;5:2119–26.
  • Scharbert G, Kalb M, Marschalek C, Kozek-Langenecker SA. The effects of test temperature and storage temperature on platelet aggregation: a whole blood in vitro study. Anesth Analg 2006;102:1280–4.
  • Kaiser AF, Neubauer H, Franken CC, Krüger JC, Mügge A, Meves SH. Which is the best anticoagulant for whole blood aggregometry platelet function testing? Comparison of six anticoagulants and diverse storage conditions. Platelets 2012;23:359–67.
  • Kander T, Brokopp J, Erlinge D, Lood C, Schött U. Temperature effects on haemostasis in whole blood from ticagrelor- and aspirin-treated patients with acute coronary syndrome. Scand J Clin Lab Invest 2015;75:27–35.
  • Bochsen L, Johansson PI, Kristensen AT, Daugaard G, Ostrowski SR. The influence of platelets, plasma and red blood cells on functional haemostatic assays. Blood Coagul Fibrinolysis 2011;22:167–75.
  • Valles J, Santos MT, Marcus AJ, Safier LB, Broekman MJ, Islam N, Ullman HL, Aznar J. Down-regulation of human platelet reactivity by neutrophils - participation of lipoxygenase derivatives and adhesive proteins. J Clin Invest 1993;92:1357–65.
  • Kavakli K, Polat A, Hüseyinof A, Nisli G, Aydinok Y. Plasma platelet-activating factor (PAF) levels and desmopressin response in children with hemophilia A and von Willebrand's disease. Thromb Haemost 1999;81:665–6.
  • Hashemi S, Palmer DS, Aye MT, Ganz PR. Platelet-activating factor secreted by DDAVP-treated monocytes mediates von Willebrand factor release from endothelial cells. J Cell Physiol 1993;154:496–505.
  • Kaufmann JE, Oksche A, Wollheim CB, Günther G, Rosenthal W, Vischer UM. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest 2000;106:107–16.
  • Kalb ML, Potura L, Scharbert G, Kozek-Langenecker SA. The effect of ex vivo anticoagulants on whole blood platelet aggregation. Platelets 2009;20:7–11.
  • Wallén NH, Ladjevardi M, Albert J, Bröijersén A. Influence of different anticoagulants on platelet aggregation in whole blood; A comparison between citrate, low molecular mass heparin and hirudin. Thromb Res 1997;87:151–7.
  • Mann KG, Whelihan MF, Butenas S, Orfeo T. Citrate anticoagulation and the dynamics of thrombin generation. J Thromb Haemost 2007;5:2055–61.
  • Saleem A, Blifeld C, Saleh SA, Yawn DH, Mace ML, Schwartz M, Crawford ES. Viscoelastic measurement of clot formation: a new test of platelet function. Ann Clin Lab Sci 1983;13:115–24.
  • Di Perna C, Riccardi F, Franchini M, Rivolta GF, Pattacini C, Tagliaferri A. Clinical efficacy and determinants of response to treatment with desmopressin in mild hemophilia a. Semin Thromb Hemost 2013;39:732–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.